Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

RNA

RNA-editing company Korro Bio snags $91.5 million in series A funding

by Megha Satyanarayana
September 20, 2020 | A version of this story appeared in Volume 98, Issue 36

 

Korro Bio has raised $91.5 million in series A funding to help advance therapeutics created through its Opera (oligonucleotide-promoted editing of RNA) platform. Similar to CRISPR-based gene editing, in which an enzyme is led to an exact spot in DNA with the help of a guide, Opera uses a human enzyme to swap out errant nucleotides in RNA, either to create modified proteins for therapeutic use or to restore beneficial function to mutated proteins in disease. The Cambridge, Massachusetts–based company says it has proof of mechanism in animal studies.

Article:

This article has been sent to the following recipient:

1 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.